"I am glad to be in the Guinness Book as the fattest man. I am also happy to have lost 200 kilos," Manuel Uribe, 41, told AFP.
Uribe was able to leave his home in Monterrey, northern Mexico in March aboard a trailer to celebrate his weight loss.

Guinness has recognized his weighty achievement with a glass plaque.
"They gave it to me, I have it in my hands," said Uribe, who founded an organization to help overweight people.

Uribe's photograph appears in the 2008 Guinness Book of Records alongside a description of the treatment he has had and offers of surgery he has received.

Uribe said the editor of the book had promised to visit him next year, and held out the possibility of appearing in the 2009 edition as the man who had lost the most weight.

Uribe appeared on television in 2006 seeking help for his excess weight, which has plagued him for more than 20 years, most of which he has spent in bed.

source:http://news.yahoo.com/s/afp/20070720/od_afp/mexicohealthobesity_070720210958

Five years ago, scientists at Wake Forest University School of Medicine were surprised to find the drug orlistat (Xenical or Alli) could kill cancer cells. Now, they report on how it works. The drug binds and interacts with a protein found in tumor cells, blocking its function and causing the cells to die.

The protein is known as fatty acid synthase. It is found in many tumor cells including those of the prostate, breast, colon, ovaries, liver, lung, and brain.

“High levels of fatty acid synthase correlate with a poor prognosis, so it is a great treatment target," assistant professor Steven Kridel, Ph.D., of Wake Forest University School of Medicine, was quoted as saying. "This makes an exciting treatment target because, theoretically, you don't have to worry about harming nearby healthy tissue."

Researchers say Alli or Xenical (orlistat) alone cannot treat cancer because while the drug can kill cancer cells in the lab, it is designed to act only in the digestive tract in humans. Now, the goal is to develop a drug like orlistat that can go through the bloodstream to the site of the tumor.

Wake Forest scientists have screened hundreds of thousands of compounds to find the ones that interact with cancer cells like orlistat does. They have narrowed down the list to a dozen and will now work to optimize the compounds to determine if they can create a potent cancer treatment.

Fatty acid synthase is also found in fat cells. This suggests if scientists successfully develop a drug to treat cancer, it could also be used to treat obesity.

Most people who shed pounds using weight-loss alli diet pill will not be able to keep the weight off. Unlike other prescription weight-loss diet drugs such as Phentermine, adipex and meridia, Alli diet pill doesn't make you feel full, reduce cravings or curb your appetite. Instead, it prevents the body from breaking down and absorbing fat.

The active ingredient in Alli diet pill is orlistat, which is found in a higher dose in the prescription diet drug Xenical. Alli diet pill blocks about 25 percent of the fat you eat; Xenical blocks one-third of the fat you ingest. For instance, a half-cup serving of Haagen-Dazs ice cream has about 320 calories and 19 grams of fat.

Alli diet pill, which is taken with meals, would prevent the body from absorbing about 4.75 fat grams or about 43 calories. If you consume about 2,000 calories a day and eat about 30 percent fat, the fat-blocking benefits of Alli diet pill would translate to about 150 calories a day. A pound of weight loss equals 3,500 calories.

To avoid the side effects, limiting fat intake to 15 grams a meal. Many Americans consume 80 to 100 grams of fat every day. Glaxo officials concede that many people would lose weight on their own with a diet that's moderate in fat, but that the pill helps them lose more weight. If you would lose 10 pounds on a diet, you'll lose 15 pounds by adding Alli diet pill to your diet.

If someone is consuming a diet already low in fat and high in carbohydrates, they likely would not get much benefit from Alli diet pill. However, doctors say most people are eating far more fat than they realize.

Orlistat has been used by an estimated 28 million people worldwide and studied in 30,000 subjects in about 100 trials. In a 1999 Journal of the American Medical Association report, 1,187 dieters, who weighed an average of 220 pounds, took either a placebo or 120 mg of orlistat (twice the dose of Alli diet pill). After one year, individuals in the orlistat group lost an average of 19.27 pounds, about 50 percent more than the 12.8-pound average weight loss in the placebo group.

But as with most diets, the dieters couldn't keep the weight off. During the second year of the study, the orlistat users were given either the 120 mg dose or switched to 60 mg, the same dose in Alli diet pill. After a year, the 120 mg users gained back seven pounds, the 60 mg users gained 9.4 pounds and the placebo group gained 11.3 pounds. So after two years on the drug, the dieters lost an average of between 10 and 12 pounds — or about 5 percent of their body weight. The placebo dieters lost 1.5 pounds.

Some dieters lost far more weight. About 50 percent of the people who use orlistat. lose at least 5 percent of their body weight. One out of five people who take the drug lose at least 10 percent of their body weight.

Pharmacies are reporting brisk sales of Alli, which is sold by drug maker GlaxoSmithKline and is the first over-the-counter diet drug to win FDA approval. Unlike other prescription weight-loss drugs such as Meridia and the generic phentermine, Alli doesn't make you feel full, reduce cravings or curb your appetite. Instead, it prevents the body from breaking down and absorbing fat.

The active ingredient in Alli is orlistat, which is found in a higher dose in the prescription diet drug Xenical. Alli blocks about 25% of the fat you eat; Xenical blocks one-third of the fat you ingest. Alli, which is taken with meals, would prevent the body from absorbing about 4.75 fat grams or about 43 calories.

The downside of Alli is the fat it blocks can come out of your body in embarrassing ways. Glaxo said that drug can cause gas with oily discharge as well as frequent or loose stools. The site suggests it's probably a "smart idea" to wear dark pants and bring a change of clothes to work if you use Alli.

To avoid the side effects, Glaxo suggests limiting fat intake. Glaxo officials concede that many people would lose weight on their own with a diet that's moderate in fat, but that the pill helps them lose more weight.

If you'd lose 10 pounds on a diet, you'll lose 15 pounds by adding Alli to your diet.

If someone is consuming a diet already low in fat and high in carbohydrates, they likely won't get much benefit from Alli. However, doctors say most people are eating far more fat than they realize.

Orlistat has been used by an estimated 28 million people world-wide, and studied in 30,000 subjects in about 100 trials. But as with most diets, the dieters couldn't keep the weight off. During the second year of the study, the Orlistat users were given either the 120 mg dose or switched to 60 mg, the same dose in Alli.

Some dieters lost far more weight. About 50% of the people who use Orlistat lose at least 5% of their body weight. One out of five people who take the drug lose at least 10% of their body weight, according to Glaxo.

Even small amounts of weight loss offer clear-cut health benefits. It's not for the average person who wants to take it and doesn't want to change their diet. It's for someone who is committed to making a change in diet and lifestyle.

Now you know there's no magic pill to lose weight, but doctors say Alli has some promise because it prevents the body from absorbing fat.

The new pill is called Alli. It’s taken three times a day with a low-calorie diet. Doctors say you'll lose weight, but if you eat food in high in fat, you'll feel it.

You don't want to go too far in depth because they're pretty nasty.

Alli works by preventing fats from being absorbed in your body. The bacteria see the fat coming and they have a party in your gut on the left over food and you’re in for some trouble.

On Alli's website it lists gas with oily spotting and loose stool as part of the treatment effects.

People want a magic way to weight loss, they don't want there intake to be the problem they don't want foods to be the problem and they don't want to their couch potato habits to be the problem they just want a miracle.

These treatment effects however have not kept people from cleaning off the shelves at the Dunes Family Pharmacy. The pharmacy has sold out, and is waiting on another shipment.

“It looks like its a drug that’s going to be sold out its going to be hard to get hopefully the supplier will be able to keep up with the demand so we can be able to keep it on stock,” says Benzoni.

Diet and exercise are key to losing weight, with or without Alli or other weight loss programs.

Alli is sold at all major drug and grocery stores in the area, but buying these diet pills on won't come cheap. 60 pills will set you back about 70 bucks.

A fat absorption pill, Alli has labeled itself as an over the counter non-prescription "drug," but its marketing places heavy emphasis on its role as a supplement to a healthy lifestyle – the sort of remedy marketing, the researchers argue, that promote the pill's chances of working by encouraging complementary healthy behaviors such as exercise.

First, drug marketing undermines motivation to live a healthy lifestyle – why bother eating low-fat foods when a drug exists to fight fat for me. Drugs also appear to weaken consumers' beliefs in their ability to live a healthy lifestyle by eating right and exercising.

Interestingly, in a series of experiments and test groups, the researchers found that supplements did not have this same 'boomerang effect" on a healthy lifestyle: regardless of how effective the supplement actually is, consumer perceptions of supplements are that they require "supplementary" behavior in order to work.

People appear to choose supplements almost as a matter of faith rather than science. They perceive these products as 'natural' and figure they can't hurt. And our research suggests that they don't - at least in terms of healthy lifestyle intentions.

These findings add to the growing debate over the regulation of drug and supplement markets and the role of direct-to-consumer advertising. Alli marketing campaign – which emphasizes the pill's role in a healthy lifestyle that also includes menu planning and exercise – may soon lead other pharmaceutical companies to follow suit and play down the effectiveness of their products.

More truthful approach to the marketing of these kinds of products may not be what consumers want to hear, but is promising because it is so different than the typical approach used to market these kinds of products. Usually, they are positioned as effective as some kind of easy, magic solution. This product is up front in educating consumers that the road to long term weight loss goals requires hard work and a long term commitment. Its effectiveness is maximized in conjunction with other behaviors.

Alli has the right balance, but the present research suggests that Glaxo Smith Kline is moving in the right direction to protect consumer welfare. "Even highly educated consumers and consumers who have otherwise acknowledged the importance of a healthy lifestyle is nonetheless susceptible to the boomerang effect for drugs.

An FDA spokeswoman said that the deliberations of the panel boiled down to, “Is the risk worth the benefit of this drug, and the panel said no."

The FDA is due to make a decision on the approval for sale in the U.S. of Acomplia, known generically as Rimonabant, in late July.
Historically, the FDA follows the advice of the advisory committee when making approval decisions.

FDA proposed that the vote against Acomplia was 14-0.

Paris-based Sanofi-Aventis (SNY) issued a statement that it “will continue to work closely with the FDA to address the committee's recommendations."

In a report prepared by the panel and published, concerns were raised about the safety of Acomplia, particularly its effect on users' mental health. Sanofi-Aventis submitted data and analyses on Acomplia for the panel's review late last year.

"Adverse events" encountered during the testing of the drug included” depressive events, anxiety, psychomotor agitation, and sleep disorders," according to the panel's report.

The FDA's Division of Metabolism and Endocrine Products has received a number of "event" reports from Sanofi-Aventis related to Acomplia, the report said, including "4 reports of delusional symptoms, 6 reports of psychotic behavior, and 5 reports of aggression".

Rimonabant, the generic form of Acomplia, is approved in 37 countries and marketed in 18, according to Sanofi-Aventis.

The notes were posted by US health experts, as is customary; decide whether to recommend the drug to the FDA health regulator for marketing approval.

Acomplia or rimonabant is an anorectic anti-obesity drug. It is a CB1 cannabinoid receptor antagonist. Its main avenue of effect is reduction in appetite. Rimonabant is currently being sold in the United Kingdom by Sanofi-Aventis and in Denmark by Sanofi-Synthelabo under the trade name Acomplia. It is believed, although not confirmed, that if the drug is approved in the United States, it will be sold under the trade name Zimulti.

It is being reported that the FDA is concerned over Acomplia due to it appearing to raise a person's risk of attempting to commit suicide. The drug does actually work according to the FDA who stated that over a 1 year period, when combined with a good diet a person could lose up to 5% more than they would if they just dieted.

The US FDA is set to ask an advisory panel to measure the benefits against the risks and decide if the drug should be marketed in the United States.

Sanofi-Aventis reacted warily to a U.S. health review of anti-obesity pill Acomplia, highlighting its side-effects such as suicidal thoughts.

U.S. Food and Drug Administration approved over-the-counter version of the company's orlistat prescription diet medicine. It will be one of the largest launches GSK has ever undertaken, probably one of the largest over-the-counter launches ever.

London-based Glaxo is selling the medicine without a prescription to help offset slowing revenue from its top-selling asthma drug Advair. An estimated 140 million adults in the U.S. were overweight or obese in 2004. The figures are based on body-mass index, which is calculated using a person's height and weight.

Glaxo is also preparing 250 pages of educational materials to accompany the starter pack, a Web site, 200,000 copies of a diet plan and 800,000 copies of a book to help dieters combine the pill with weight-loss programs. People who take alli while improving their diets and exercise regimens can lose 50 percent more weight.

The company is aiming the product at committed dieters who will help sustain sales rather than fad dieters who will buy alli and then drop it.

Orlistst costs about $270 for a one-month supply of 120- milligram pills and has been on the market for eight years. It brought in $90 million in the U.S. last year. The drug acts by blocking fat absorption in the stomach and intestines and doesn't affect the heart or brain.

Glaxo markets the prescription version, known as Xenical, in the U.S. through an agreement.

Glaxo plans to seek permission by the end of this year to sell the product without a prescription in Europe. About 40 percent of Europeans are overweight and 15 percent are obese.